10
Participants
Start Date
April 10, 2017
Primary Completion Date
March 25, 2020
Study Completion Date
March 25, 2020
low-dose Azacitidine
Azacitidine 75 mg/d s.c. for 7 days, repeated 28-day treatment cycle
Pioglitazone
Pioglitazone 45 mg p.o. continuously from day 1
ATRA
ATRA \*45 mg/m² p.o. from day 1 to 28, 15 mg/m² from day 29 continuously; \*this regimen will be chosen for the first dose to be evaluated.
standard-dose AZA
Azacitidine 75 mg/m²/d s.c. for 7 days, repeated 28-day treatment cycle
University Hospital Regensburg, Regensburg
Collaborators (1)
Anticancer Fund, Belgium
OTHER
Celgene
INDUSTRY
University Hospital Regensburg
OTHER